Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform
Background Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fu...
Gespeichert in:
| Veröffentlicht in: | The Journal of Prevention of Alzheimer's Disease 2024, Vol.11 (6), p.1581-1591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1591 |
|---|---|
| container_issue | 6 |
| container_start_page | 1581 |
| container_title | The Journal of Prevention of Alzheimer's Disease |
| container_volume | 11 |
| creator | Martínez-Dubarbie, Francisco Guerra-Ruiz, A. López-García, S. Lage, C. Fernández-Matarrubia, M. Infante, J. Pozueta-Cantudo, A. García-Martínez, M. Corrales-Pardo, A. Bravo, M. López-Hoyos, M. Irure-Ventura, J. Valeriano-Lorenzo, E. García-Unzueta, M. T. Sánchez-Juan, P. Rodríguez-Rodríguez, E. |
| description | Background
Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.
Objectives
To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.
Design
Cross-sectional analyses from a prospective cohort.
Setting
A population-based study.
Participants
Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.
Measurements
Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.
Results
We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value |
| doi_str_mv | 10.14283/jpad.2024.152 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11573816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130210869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-86437f482ab237bcf1e6aaed9c80a95d55db67b8a09c05dd1b664962bc52c94f3</originalsourceid><addsrcrecordid>eNp1kctu1DAYhS0EotXQLUvkJZtMfUkce4WqKaVII1EJZm05jpPxKLGDL5XmYXhXPJ1SwYKVL__xOdb5AHiP0RrXhNPrw6L6NUGkXuOGvAKXpCasQoSx12VP2rpqOGovwFWMB4QQFphRwd-CCyqaRvAWX4Jft1aNzsdkNbzROgelj9AP8GFScVZwqZLKBLdw8AHemmR0sm6EDyrt_eRHq9UENyaYLvi4WFdOd1O2PdzslRtNhNbBjR-dTfbRTEe4c3ZelA2mh99zdyhuEe7iyTHtDdzm2S55iuaUnkri_A68GVS5uHpeV2B39_nH5r7afvvydXOzrTTlLFWc1bQdak5UR2jb6QEbppTpheZIiaZvmr5jbccVEho1fY87xmrBSKcbokU90BX4dPZdcjebXhuXgprkEuyswlF6ZeW_E2f3cvSPEuOmpbzUugIfnx2C_5lNTHK2UZtpUs74HCXFFBGMOBNFuj5LdSktBjO85GAkn7jKE1d54ioL1_Lgw9-_e5H_oVgE12dBLKPSe5AHn0OhEf9n-RutfbI4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130210869</pqid></control><display><type>article</type><title>Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Martínez-Dubarbie, Francisco ; Guerra-Ruiz, A. ; López-García, S. ; Lage, C. ; Fernández-Matarrubia, M. ; Infante, J. ; Pozueta-Cantudo, A. ; García-Martínez, M. ; Corrales-Pardo, A. ; Bravo, M. ; López-Hoyos, M. ; Irure-Ventura, J. ; Valeriano-Lorenzo, E. ; García-Unzueta, M. T. ; Sánchez-Juan, P. ; Rodríguez-Rodríguez, E.</creator><creatorcontrib>Martínez-Dubarbie, Francisco ; Guerra-Ruiz, A. ; López-García, S. ; Lage, C. ; Fernández-Matarrubia, M. ; Infante, J. ; Pozueta-Cantudo, A. ; García-Martínez, M. ; Corrales-Pardo, A. ; Bravo, M. ; López-Hoyos, M. ; Irure-Ventura, J. ; Valeriano-Lorenzo, E. ; García-Unzueta, M. T. ; Sánchez-Juan, P. ; Rodríguez-Rodríguez, E.</creatorcontrib><description>Background
Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.
Objectives
To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.
Design
Cross-sectional analyses from a prospective cohort.
Setting
A population-based study.
Participants
Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.
Measurements
Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.
Results
We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value<0.001) and p-tau181 (r=0.59; p-value<0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value<0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.
Conclusions
Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.</description><identifier>ISSN: 2274-5807</identifier><identifier>ISSN: 2426-0266</identifier><identifier>EISSN: 2426-0266</identifier><identifier>DOI: 10.14283/jpad.2024.152</identifier><identifier>PMID: 39559871</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Aged ; Alzheimer Disease - blood ; Alzheimer Disease - cerebrospinal fluid ; Alzheimer Disease - diagnosis ; Amyloid beta-Peptides - blood ; Amyloid beta-Peptides - cerebrospinal fluid ; Biomarkers - blood ; Biomarkers - cerebrospinal fluid ; Cross-Sectional Studies ; Female ; Geriatrics/Gerontology ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neurology ; Original Research ; Peptide Fragments - blood ; Peptide Fragments - cerebrospinal fluid ; Prospective Studies ; tau Proteins - blood ; tau Proteins - cerebrospinal fluid</subject><ispartof>The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (6), p.1581-1591</ispartof><rights>The Authors 2024</rights><rights>The Authors 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c386t-86437f482ab237bcf1e6aaed9c80a95d55db67b8a09c05dd1b664962bc52c94f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.14283/jpad.2024.152$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.14283/jpad.2024.152$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39559871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez-Dubarbie, Francisco</creatorcontrib><creatorcontrib>Guerra-Ruiz, A.</creatorcontrib><creatorcontrib>López-García, S.</creatorcontrib><creatorcontrib>Lage, C.</creatorcontrib><creatorcontrib>Fernández-Matarrubia, M.</creatorcontrib><creatorcontrib>Infante, J.</creatorcontrib><creatorcontrib>Pozueta-Cantudo, A.</creatorcontrib><creatorcontrib>García-Martínez, M.</creatorcontrib><creatorcontrib>Corrales-Pardo, A.</creatorcontrib><creatorcontrib>Bravo, M.</creatorcontrib><creatorcontrib>López-Hoyos, M.</creatorcontrib><creatorcontrib>Irure-Ventura, J.</creatorcontrib><creatorcontrib>Valeriano-Lorenzo, E.</creatorcontrib><creatorcontrib>García-Unzueta, M. T.</creatorcontrib><creatorcontrib>Sánchez-Juan, P.</creatorcontrib><creatorcontrib>Rodríguez-Rodríguez, E.</creatorcontrib><title>Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform</title><title>The Journal of Prevention of Alzheimer's Disease</title><addtitle>J Prev Alzheimers Dis</addtitle><addtitle>J Prev Alzheimers Dis</addtitle><description>Background
Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.
Objectives
To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.
Design
Cross-sectional analyses from a prospective cohort.
Setting
A population-based study.
Participants
Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.
Measurements
Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.
Results
We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value<0.001) and p-tau181 (r=0.59; p-value<0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value<0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.
Conclusions
Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.</description><subject>Aged</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - cerebrospinal fluid</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Amyloid beta-Peptides - blood</subject><subject>Amyloid beta-Peptides - cerebrospinal fluid</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - cerebrospinal fluid</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Geriatrics/Gerontology</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Original Research</subject><subject>Peptide Fragments - blood</subject><subject>Peptide Fragments - cerebrospinal fluid</subject><subject>Prospective Studies</subject><subject>tau Proteins - blood</subject><subject>tau Proteins - cerebrospinal fluid</subject><issn>2274-5807</issn><issn>2426-0266</issn><issn>2426-0266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctu1DAYhS0EotXQLUvkJZtMfUkce4WqKaVII1EJZm05jpPxKLGDL5XmYXhXPJ1SwYKVL__xOdb5AHiP0RrXhNPrw6L6NUGkXuOGvAKXpCasQoSx12VP2rpqOGovwFWMB4QQFphRwd-CCyqaRvAWX4Jft1aNzsdkNbzROgelj9AP8GFScVZwqZLKBLdw8AHemmR0sm6EDyrt_eRHq9UENyaYLvi4WFdOd1O2PdzslRtNhNbBjR-dTfbRTEe4c3ZelA2mh99zdyhuEe7iyTHtDdzm2S55iuaUnkri_A68GVS5uHpeV2B39_nH5r7afvvydXOzrTTlLFWc1bQdak5UR2jb6QEbppTpheZIiaZvmr5jbccVEho1fY87xmrBSKcbokU90BX4dPZdcjebXhuXgprkEuyswlF6ZeW_E2f3cvSPEuOmpbzUugIfnx2C_5lNTHK2UZtpUs74HCXFFBGMOBNFuj5LdSktBjO85GAkn7jKE1d54ioL1_Lgw9-_e5H_oVgE12dBLKPSe5AHn0OhEf9n-RutfbI4</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Martínez-Dubarbie, Francisco</creator><creator>Guerra-Ruiz, A.</creator><creator>López-García, S.</creator><creator>Lage, C.</creator><creator>Fernández-Matarrubia, M.</creator><creator>Infante, J.</creator><creator>Pozueta-Cantudo, A.</creator><creator>García-Martínez, M.</creator><creator>Corrales-Pardo, A.</creator><creator>Bravo, M.</creator><creator>López-Hoyos, M.</creator><creator>Irure-Ventura, J.</creator><creator>Valeriano-Lorenzo, E.</creator><creator>García-Unzueta, M. T.</creator><creator>Sánchez-Juan, P.</creator><creator>Rodríguez-Rodríguez, E.</creator><general>Springer International Publishing</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2024</creationdate><title>Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform</title><author>Martínez-Dubarbie, Francisco ; Guerra-Ruiz, A. ; López-García, S. ; Lage, C. ; Fernández-Matarrubia, M. ; Infante, J. ; Pozueta-Cantudo, A. ; García-Martínez, M. ; Corrales-Pardo, A. ; Bravo, M. ; López-Hoyos, M. ; Irure-Ventura, J. ; Valeriano-Lorenzo, E. ; García-Unzueta, M. T. ; Sánchez-Juan, P. ; Rodríguez-Rodríguez, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-86437f482ab237bcf1e6aaed9c80a95d55db67b8a09c05dd1b664962bc52c94f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - cerebrospinal fluid</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Amyloid beta-Peptides - blood</topic><topic>Amyloid beta-Peptides - cerebrospinal fluid</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - cerebrospinal fluid</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Geriatrics/Gerontology</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Original Research</topic><topic>Peptide Fragments - blood</topic><topic>Peptide Fragments - cerebrospinal fluid</topic><topic>Prospective Studies</topic><topic>tau Proteins - blood</topic><topic>tau Proteins - cerebrospinal fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez-Dubarbie, Francisco</creatorcontrib><creatorcontrib>Guerra-Ruiz, A.</creatorcontrib><creatorcontrib>López-García, S.</creatorcontrib><creatorcontrib>Lage, C.</creatorcontrib><creatorcontrib>Fernández-Matarrubia, M.</creatorcontrib><creatorcontrib>Infante, J.</creatorcontrib><creatorcontrib>Pozueta-Cantudo, A.</creatorcontrib><creatorcontrib>García-Martínez, M.</creatorcontrib><creatorcontrib>Corrales-Pardo, A.</creatorcontrib><creatorcontrib>Bravo, M.</creatorcontrib><creatorcontrib>López-Hoyos, M.</creatorcontrib><creatorcontrib>Irure-Ventura, J.</creatorcontrib><creatorcontrib>Valeriano-Lorenzo, E.</creatorcontrib><creatorcontrib>García-Unzueta, M. T.</creatorcontrib><creatorcontrib>Sánchez-Juan, P.</creatorcontrib><creatorcontrib>Rodríguez-Rodríguez, E.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of Prevention of Alzheimer's Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez-Dubarbie, Francisco</au><au>Guerra-Ruiz, A.</au><au>López-García, S.</au><au>Lage, C.</au><au>Fernández-Matarrubia, M.</au><au>Infante, J.</au><au>Pozueta-Cantudo, A.</au><au>García-Martínez, M.</au><au>Corrales-Pardo, A.</au><au>Bravo, M.</au><au>López-Hoyos, M.</au><au>Irure-Ventura, J.</au><au>Valeriano-Lorenzo, E.</au><au>García-Unzueta, M. T.</au><au>Sánchez-Juan, P.</au><au>Rodríguez-Rodríguez, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform</atitle><jtitle>The Journal of Prevention of Alzheimer's Disease</jtitle><stitle>J Prev Alzheimers Dis</stitle><addtitle>J Prev Alzheimers Dis</addtitle><date>2024</date><risdate>2024</risdate><volume>11</volume><issue>6</issue><spage>1581</spage><epage>1591</epage><pages>1581-1591</pages><issn>2274-5807</issn><issn>2426-0266</issn><eissn>2426-0266</eissn><abstract>Background
Plasma biomarkers of Alzheimer’s disease (AD), especially p-tau217, are promising tools to identify subjects with amyloid deposition in the brain, determined either by cerebrospinal fluid (CSF) or positron emission tomography. However, it is essential to measure them in an accurate and fully automated way in order to apply them in clinical practice.
Objectives
To evaluate the diagnostic performance of the fully-automated Lumipulse plasma p-tau217 assay in preclinical AD.
Design
Cross-sectional analyses from a prospective cohort.
Setting
A population-based study.
Participants
Volunteers over 55 years without cognitive impairment or contraindications for complementary tests.
Measurements
Plasma p-tau217 was measured with the fully-automated Lumipulse assay, as well as CSF Aβ40, Aβ42, p-taul81, and t-tau levels. We correlated plasma p-tau217 with CSF Aβ40, Aβ42 and p-tau181, and assessed the differences in plasma p-tau217 according to CSF amyloid status (A−/+), AD status (AD+ being those subjects A+T+ and AD- the rest) and ATN group. We performed ROC curves and measured the areas under the curve (AUC) using CSF amyloid as result, and both p-tau217 and ApoE4 status as predictor.
Results
We screened 209 cognitively unimpaired volunteers with a mean age 64 years (60–69) and 30.2% of ApoE4 carriers. Plasma p-tau217 correlated significantly with CSF Aβ42/Aβ40 (Rho=−0.51; p-value<0.001) and p-tau181 (r=0.59; p-value<0.001). Its levels were significantly higher in A+ subjects (0.26 pg/ml) compared with A- (0.12 pg/ml; p-value<0.001); and along ATN groups. It predicts CSF amyloid pathology with an AUC of 0.85.
Conclusions
Plasma p-tau217 measured using the Lumipulse platform shows promise as an accurate biomarker of preclinical AD pathology.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>39559871</pmid><doi>10.14283/jpad.2024.152</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2274-5807 |
| ispartof | The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (6), p.1581-1591 |
| issn | 2274-5807 2426-0266 2426-0266 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11573816 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Alzheimer Disease - blood Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - diagnosis Amyloid beta-Peptides - blood Amyloid beta-Peptides - cerebrospinal fluid Biomarkers - blood Biomarkers - cerebrospinal fluid Cross-Sectional Studies Female Geriatrics/Gerontology Humans Male Medicine Medicine & Public Health Middle Aged Neurology Original Research Peptide Fragments - blood Peptide Fragments - cerebrospinal fluid Prospective Studies tau Proteins - blood tau Proteins - cerebrospinal fluid |
| title | Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T07%3A27%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20Accuracy%20of%20Plasma%20p-tau217%20for%20Detecting%20Pathological%20Cerebrospinal%20Fluid%20Changes%20in%20Cognitively%20Unimpaired%20Subjects%20Using%20the%20Lumipulse%20Platform&rft.jtitle=The%20Journal%20of%20Prevention%20of%20Alzheimer's%20Disease&rft.au=Mart%C3%ADnez-Dubarbie,%20Francisco&rft.date=2024&rft.volume=11&rft.issue=6&rft.spage=1581&rft.epage=1591&rft.pages=1581-1591&rft.issn=2274-5807&rft.eissn=2426-0266&rft_id=info:doi/10.14283/jpad.2024.152&rft_dat=%3Cproquest_pubme%3E3130210869%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130210869&rft_id=info:pmid/39559871&rfr_iscdi=true |